Victoza and Ozempic are both GLP-1 receptor agonists used to treat type 2 diabetes. They share the same drug class, similar side-effect profiles, and cardiovascular outcome benefits — but they differ in molecule, dosing frequency, and potency. This guide breaks down a side-by-side comparison: efficacy, weight loss, cardiovascular data, dosing, side effects, pediatric use, and cost.
Victoza vs Ozempic at a Glance
| Feature | Victoza | Ozempic |
|---|---|---|
| Active ingredient | Liraglutide | Semaglutide |
| Drug class | GLP-1 receptor agonist | GLP-1 receptor agonist |
| Dosing frequency | Once daily subcutaneous injection | Once weekly subcutaneous injection |
| Dose range | 0.6 to 1.8 mg daily | 0.25 to 2.0 mg weekly |
| Half-life | about 13 hours | about 7 days |
| A1C reduction | about 1.0 to 1.5 percent | about 1.5 to 2.0 percent |
| Weight loss | 2 to 3 kg | 5 to 7 kg |
| CV outcomes trial | LEADER (2016) | SUSTAIN-6 (2016), SELECT (2023) |
| FDA pediatric approval | Yes (age 10+) | No (adults only) |
| List price (monthly) | about $850 | about $950 to $1,000 |
| Boxed warning | Thyroid C-cell tumors | Thyroid C-cell tumors |
Efficacy — A1C and Weight Loss
The SUSTAIN-10 trial directly compared semaglutide 1.0 mg weekly with liraglutide 1.2 mg daily in adults with type 2 diabetes. Results at 30 weeks:
| Outcome | Semaglutide 1.0 mg weekly | Liraglutide 1.2 mg daily |
|---|---|---|
| A1C reduction | -1.7 percent | -1.0 percent |
| Weight loss | -5.8 kg | -1.9 kg |
| Reached A1C below 7 percent | 80 percent | 62 percent |
The maximum Victoza dose for diabetes is 1.8 mg daily — somewhat higher than the 1.2 mg used in SUSTAIN-10 — which closes some of the gap. Real-world A1C reductions on Victoza 1.8 mg are typically 1.0 to 1.5 percent. Ozempic 1.0 mg weekly typically achieves 1.5 percent, and the 2.0 mg dose can reach 2.0 percent.
Cardiovascular Outcomes
Both drugs have demonstrated reductions in major adverse cardiovascular events (MACE) in dedicated trials.
- LEADER (Victoza, 2016). 9,340 adults with type 2 diabetes and established CV disease or high CV risk. Over a median 3.8 years, liraglutide reduced MACE (CV death, nonfatal MI, nonfatal stroke) by about 13 percent compared with placebo (HR 0.87). All-cause mortality reduced by about 15 percent.
- SUSTAIN-6 (Ozempic, 2016). 3,297 adults with type 2 diabetes at high CV risk. Over a median 2.1 years, semaglutide reduced MACE by about 26 percent (HR 0.74). A small signal of diabetic retinopathy complications emerged in semaglutide users — patients with preexisting retinopathy should have eye monitoring.
- SELECT (Ozempic-class semaglutide, 2023). 17,604 adults with obesity (without diabetes) and established CV disease. Semaglutide 2.4 mg weekly (Wegovy dose) reduced MACE by about 20 percent over a mean 3.3 years.
Dosing — How They Compare in Practice
| Step | Victoza | Ozempic |
|---|---|---|
| Starter dose | 0.6 mg daily for at least 1 week | 0.25 mg weekly for 4 weeks |
| Effective dose | 1.2 mg daily after 1 week | 0.5 mg weekly after 4 weeks |
| Higher dose | 1.8 mg daily (maximum for T2D) | 1.0 mg weekly after 4 more weeks |
| Maximum dose | 1.8 mg daily | 2.0 mg weekly |
| Pen storage | Refrigerate; room temp for 30 days after first use | Refrigerate; room temp for 56 days after first use |
Weekly dosing is a major practical advantage for many people. One injection per week (Ozempic) vs seven per week (Victoza) translates to fewer needles, fewer site rotations, and easier travel.
Side-Effect Profile Comparison
| Side Effect | Victoza (1.8 mg) | Ozempic (1.0 mg) |
|---|---|---|
| Nausea | about 28 percent | about 20 percent |
| Diarrhea | about 17 percent | about 9 percent |
| Vomiting | about 11 percent | about 9 percent |
| Constipation | about 10 percent | about 5 percent |
| Decreased appetite | about 11 percent | about 7 percent |
| Injection site reactions | about 2 percent | about 1 percent |
Both drugs share serious-but-uncommon risks including acute pancreatitis, gallbladder disease, acute kidney injury secondary to dehydration, and a boxed warning for thyroid C-cell tumors based on rodent data. Both are contraindicated in personal or family history of medullary thyroid carcinoma or MEN2.
Pediatric Use
Victoza is FDA-approved for type 2 diabetes in adolescents 10 years and older — the only injectable GLP-1 receptor agonist with pediatric approval. Ozempic is approved for adults only. For children and teens with type 2 diabetes who need a GLP-1 RA, Victoza remains the established option.
Practical Considerations
- Daily versus weekly injection. If you prefer fewer injections or travel often, Ozempic’s weekly dosing is simpler. If you forget weekly doses but remember daily routines, Victoza may be easier to integrate.
- Adherence and flexibility. A missed weekly Ozempic injection can be made up if it has been less than 5 days; otherwise skip and resume on the regular day. A missed daily Victoza injection is simply taken with the next day’s dose at the regular time — do not double up.
- Side-effect tolerance. Victoza tends to have slightly higher nausea and diarrhea rates at 1.8 mg than Ozempic at 1.0 mg in trial data. Daily dosing also means daily exposure peaks that some people find more bothersome.
- Cost. List prices are similar. Coverage depends on individual insurance plans. Patient assistance programs are available from Novo Nordisk for both.
- Cardiovascular history. Both have demonstrated CV benefit; choose based on patient and clinician preference if CV outcomes are the priority.
Switching Between Them
- Victoza 1.2 mg daily to Ozempic. Start Ozempic 0.25 mg weekly the day after the last Victoza injection; escalate to 0.5 mg at week 5, 1.0 mg at week 9 if needed.
- Victoza 1.8 mg daily to Ozempic. Start Ozempic 0.5 mg weekly directly the day after the last Victoza injection; escalate to 1.0 mg at week 5 if needed.
- Ozempic to Victoza. Wait 7 days after last weekly Ozempic injection, then start Victoza 0.6 mg daily for 1 week, then 1.2 mg or 1.8 mg as appropriate.
Who Should Choose Which
- Consider Victoza if: the patient is a child or adolescent (10 to 17), if the patient prefers daily routine over weekly remembering, if insurance covers Victoza but not Ozempic, or if a slower-acting agent is preferred at start.
- Consider Ozempic if: the patient wants the most effective glycemic and weight outcomes, prefers weekly injection, has obesity in addition to type 2 diabetes, or has had limited tolerance to daily injection routines.
Related Reading
For more on these medications, see our pages on Victoza for type 2 diabetes, Saxenda versus Victoza (the higher-dose liraglutide formulation for weight loss), how Rybelsus compares with Ozempic, and the GLP-1 drug class overview. For broader treatment context, see our treatment hub and A1C levels guide. The cardiovascular outcomes data is summarized in the ADA Standards of Care 2024.
The Bottom Line
Victoza and Ozempic are both GLP-1 receptor agonists for type 2 diabetes from the same manufacturer. Ozempic (semaglutide, weekly) produces larger A1C reductions and more weight loss than Victoza (liraglutide, daily), and is generally preferred when maximum glycemic and weight outcomes are the goal. Victoza retains advantages — pediatric approval down to age 10, an established cardiovascular outcomes record from LEADER, and a slightly lower list price. Side-effect profiles are similar; both carry the class boxed warning for thyroid C-cell tumors. Talk with your clinician about which fits your goals, age, and preference for dosing frequency.
